Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Bsf Enterprise Plc | LSE:BSFA | London | Ordinary Share | GB00BHNBDQ51 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.875 | 26,000 | 07:34:30 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 2.75 | 3.00 | 2.875 | 2.875 | 2.875 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 13k | -1.5M | -0.0145 | -1.98 | 2.97M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 11:09:23 | O | 26,000 | 2.81 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 08/11/2024 | 07:00 | UK RNS | BSF Enterprise PLC Portfolio Update |
| 26/9/2024 | 06:00 | UK RNS | BSF Enterprise PLC Portfolio Update |
| 12/8/2024 | 18:42 | ALNC |  IN BRIEF: BSF Enterprise strikes deal with University of Montreal |
| 12/8/2024 | 06:00 | UK RNS | BSF Enterprise PLC Kerato Ltd Partners with University of Montreal |
| 18/6/2024 | 06:00 | UK RNS | BSF Enterprise PLC Director/PDMR Shareholding |
| 17/6/2024 | 06:00 | UK RNS | BSF Enterprise PLC Director/PDMR Shareholding |
| 14/6/2024 | 09:47 | UK RNS | BSF Enterprise PLC Director/PDMR Shareholding |
| 13/6/2024 | 06:00 | UK RNS | BSF Enterprise PLC Grant of Options |
| 11/6/2024 | 13:29 | ALNC | BSF agreements with leading brands validates market potential says CEO |
| 11/6/2024 | 06:00 | UK RNS | BSF Enterprise PLC Interim Results |
Bsf Enterprise (BSFA) Share Charts1 Year Bsf Enterprise Chart |
|
1 Month Bsf Enterprise Chart |
Intraday Bsf Enterprise Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 19/11/2024 | 17:47 | BSF Enterprise: Bio-Sustainable Future | 1,868 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 11:09:24 | 2.81 | 26,000 | 730.60 | O |
| 2024-11-20 15:29:22 | 3.00 | 75,000 | 2,250.00 | O |
| 2024-11-20 14:58:54 | 2.99 | 5,994 | 179.07 | O |
| 2024-11-20 13:58:55 | 3.00 | 5,000 | 149.75 | O |
| 2024-11-20 13:10:41 | 2.99 | 75,000 | 2,242.50 | O |
| Top Posts |
|---|
Posted at 21/11/2024 08:20 by Bsf Enterprise Daily Update Bsf Enterprise Plc is listed in the Finance Services sector of the London Stock Exchange with ticker BSFA. The last closing price for Bsf Enterprise was 2.88p.Bsf Enterprise currently has 103,336,937 shares in issue. The market capitalisation of Bsf Enterprise is £2,965,770. Bsf Enterprise has a price to earnings ratio (PE ratio) of -1.98. This morning BSFA shares opened at 2.88p |
Posted at 24/9/2024 12:29 by le mass du pap Volume picking up again. Worth listening to Sunday Roast interview. Major fashion house talks in Paris with news soon regarding leather and sales of City mix in the millions on the cards. Things might finally be about to happen and at this mcap it's a no brainer imho. Good summary by Myles Mcnulty on Twitter.Myles McNulty @MylesMcNulty Afternoon Charles, a decent write up on #BSFA 👏 Follows on from a really informative interview on @RoastPR over the weekend. The UK markets are currently unforgiving, and will completely ignore comapnies just talking the talk. Story stocks like BSF need to to deliver on promises, need to actually walk the walk. We need to start seeing revenue generation from sales of City-Mix and its new sister product, Cyto-Boost. City-Mix for leather production and cultivated meat production; Cyto-Boost for the biopharma sector. Nevertheless, it was promising to hear about possible near-term City-Mix sales, in the weekend interview: "As we're moving closer to the first contract to supply (City-Mix), the amounts that they're going to need are huge - you're looking at multi-million-pound annual gross profits, just from that one (cultivated meat) company" It was even more promising to hear that the team were in Paris this weekend just gone, meeting "one of the largest fashion houses in the world...." (which they say is a different one to their existing partner in the space). So they've been working with - or are in commercial discussions with - at least two out of Hermes, Kering, LVMH, etc. To note: Agronomics' investee company, GALY -which creates cultivated cotton - is valued at $100m, after its raise this month. Another ANIC investee company, VitroLabs - which also produces cultivated leather (but which requires plant scaffolds, unlike BSFA) - was valued at $128m, after its May 2022 raise. These are the closest peers to BSF's 100%-owned subsidiary, Lab Grown Leather Ltd. BSFA's mkt cap is currently $5m. Land a contract with a major fashion house, and there is no reason that LGL shouldn't be aiming for similar valuations (i.e. 20-25x uplift from BSF's current mkt cap). And that's just for 1 out of 4 of BSF's business lines. BSF has been a terrible hold over the past 20 months (I should have exited within 2 months of entry, for +200% after that first major run up!) - but I'm confident it'll turn soon enough. hxxp://audioboom.com |
Posted at 23/4/2024 11:15 by le mass du pap Been a few on here, LSE and of course X/twitter trying to spread fear about a discounted placing. This has obviously affected sentiment and therefore the price. The company clearly stated in a recent RNS that they are funded and have no plans to do a fundraise. I've just seen this email, again confirming there are no plans for a placing and there has been no change in that position. Not sure how much clearer the company could be. Of course that won't stop the usual suspects from playing their games. BSFA is very oversold imho.Dear, Thank you for your email. BSF Enterprise continues to progress and achieve its strategic objectives laid out at the beginning of the year. The Company is sufficiently funded for all near-term activity and has no current plans for a fundraise. Any additional funding may be achieved at a subsidiary level to prevent the dilution of shareholders. There has been no change in that position Thank you for your continued support. Regards, Miao He BSF Enterprise PLC |
Posted at 11/4/2024 11:59 by simonsmithiv This share is the equivalent of expecting sun and getting drizzle. |
Posted at 28/11/2023 13:50 by sphere25 Had a go here last November (15th November 2022 Post 37) on the major news that day. It worked out well for a trade, but a year on, still sat here wondering the same thing:"When you look at these announcements, you sit and wonder just how far these things could go and how big they could eventually get. The problem is it is Penny Punt Land, where the reality is a minority making it really big, and losses for the near majority eventually coming to the fore. Clearly these moments of excitement can provide profitable short term opportunities too" Looking around the market, it has just been a systematic annihilation of the majority of these sorts of penny punt/highly speculative shares. The forums are almost a testament to that, being graveyard like. It won't stop in this normalised higher rate environment - the market will continue on its brutal streak of cleansing. The update from BSFA on Friday was interesting. Major names in the mix here from the update. In a different market a highly speculative share like this goes screaming north on that update alone. In this market it is almost the theme now that a positive new release will result in limited movement higher or a quick sell back down. It goes like this: --> Positive news release --> Market makers mark the price up --> A little surge in buying that fizzles out --> Big sellers sat in the background sell into the little spike to overwhelm the buyers and kill off any momentum --> Price ends up stalling and then coming back down Watched a fair few of these, and it is almost pointless having a go, unless there is blowout buying coming in. I suspect BSFA will need at least a double digit millions day to have a chance of real momentum. I can see a little pop today with just over 2m shares trade. Myles Mcnulty along with others on X clearly have influence. Interestingly, right now they have more influence than the likes of Simon Thompson of IC, Robbie Burns (Naked Trader) and even SCSW where there is very little influence nowadays, sometimes just the odd few buys with the old guard tipsters/commentator Barring some real game changing announcement here (and elsewhere) in these highly speculative shares, I don't see how the market will change its view on them. The market will constantly look more at the need for funding (than the bullish updates) and the price will just drift expecting another placing. If you have 18 months of cash, in 6 months time the market is looking even more strongly toward the financing side, so the bullish news has to be transformational, or market sentiment has to change in a material way. That said, this is one of the few that did catch the eye last year and still looks interesting. It might be a 10/90 against sort of play, but it stays on the watchlist to see if any big buying does eventually come in. In the graveyard of hundreds, there are still the odd few that can make it big. Wonder if this is one of them. Maybe come back in another year to comment :-) All imo DYOR |
Posted at 24/11/2023 07:55 by walter walcarpets RNS Number : 5345UBSF Enterprise PLC 24 November 2023 24 November 2023 BSF Enterprise PLC ("BSF" or the "Company") 3D Bio-Tissues Product Partnership Progress BSF (LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech company and owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues (3DBT), provides an update on the Company's partnership progress across several of 3DBT's product verticals. Etsyl (TM) Commercial Update 3DBT is pleased to announce that it has entered into a proof-of-concept contractual agreement with one of the largest cosmetic companies in the world, which will test the suitability of the Company's proprietary lipopeptide product, Etsyl(TM), for use within its skin cream cosmetic solutions. 3DBT is harnessing the natural regenerative ability of human skin cells to drive rapid tissue regeneration and repair. Its Etsyl(TM) promotes cellular collagen production in human skin cells, with cosmetic and pharmacological applications as a bioactive ingredient in skincare formulations for the fabrication of native-like skin substitutes for clinical, cosmetic and industrial applications. The cosmetic company which BSF is working with specialises in the research and development of bioactive ingredients for skin care which, with proven efficacy, can aid in anti-ageing, moisturising and acne control. EIT Grant In September 2023, 3D Bio-Tissues announced that it has been awarded a EUR612,000 grant from the European Institute of Innovation and Technology ("EIT Food") to upscale the production and sales of its proprietary serum-free media, City-Mix(TM). City-Mix(TM) is an animal-free cell growth agent for culturing skin, muscle and fat cells for use in cultivated meat and leather production. Further to this, 3DBT is pleased to announce that it now has two new staff members in place to focus on securing additional procurement, manufacturing and distribution partnerships in the food-tech and biotech sectors, including Mr Adam Crosby, an operational manager with broad-level experience across multiple industries, and a successful track record in delivering multi-million-pound projects and facilitating growth. The Company has also hired an experienced Technical Sales Specialist to strengthen its sales team. Book launch Chief Executive of 3DBT, Professor Che Connon, has co-authored a book entitled Advances in Cultured Meat Technology, that explores the potential of cultured meat production in solving food security. Publication of the book is expected to further enhance Professor Connon, and the Company's international profile and reputation within the rapidly advancing cultured meat industry. Che Connon, Chief Executive of 3DBT and Managing Director of BSF said: "We are delighted to be working with one of the world's largest cosmetic companies, which highlights the potential of our Etsyl product and the diverse applications of our technology. Furthermore, with an enlarged team in hand, we hope to secure further partnerships and sales for our various product offerings at an accelerated pace, and we look to the future with confidence." For further enquiries, pleas |
Posted at 06/11/2023 08:17 by hamidahamida Interesting update indicates to me management wants higher share price and they are going to provide the fuelling RNS's in coming weeks to drive shares higher ... |
Posted at 28/9/2023 12:34 by happy bear Look, lets get real here.It's been almost a year since they presented their bits of lab meat and the share price doubled. It then went on a very rampy journey to 20p at which point they did a discounted placing. They were then meant to 'showcase' some more meat but didn't, instead they hid it behind closed doors and only invited some twitter rampers. They then said the US listing and roadshow would be the catalyst for a rerate rather than just an excuse for an all expenses paid jolly to New York to rub shoulders with other boffins, and AGAIN it's done sweet FA for the share price! Plus they're paying some expensive US PR outfit for this. They also chucked in some pie-in-the-sky teaser about leather but can't tell us who the 'leading fashion house' is and nobody seems to have found out. Oh and there was something about 'evaluations' of their citymix media, but that was over 6 months ago and the trails gone cold. Meanwhile the CEO picks up £80k a year, on top of jollies, to work 2 days a week. It's a fairy tail. |
Posted at 15/9/2023 09:00 by snowy20 Still expecting this to move up ,Finding this share annoying as any rise soon sold into .Going to take a lot of good news to move price up .In my opinion RNS such as the last RNS not helping confidence or share price . |
Posted at 30/7/2023 19:11 by simonsmithiv Basically I asked about some of the concerns people have that are likely causing the slide in the share price. For example, I asked if they were concerned that there is no US interest following the roadshow and what are the US PR consultancy actually doing. I also suggested the RNS's needed more detail rather than just riddles and a rehash of previous news.The reply I got was that they "disagree with many of your(my) assertions". They dismissed the slide in the share price as being "caused by a single seller dumping shares on the market after a good release by the Company last Monday", which is ridiculous as the share price has been in decline since the end of March. Also a large seller is surely concerning as we expected to be seeing large buyers! And that "Unfortunately the US market is taking time to get into gear", in other words it's failed, at least so far. He attached a pdf of the company's interim results and said they are pressing forward with their plans. My take is that after a very enthusiastic start the chickens are coming home to roost. The past 12 months (and probably the next 12) were always going to be about foundations and funding. I think they over egged it before the last placing and then tried to run before they could walk. It's now about doing the hard graft to get it to actually run and that's going to take time. I take issue with the way it's been handled as it has sounded quite rampy at times and buyers have been swept up in it, me included. All the big news events have ultimately fallen flat as the share price is back to where it was last November. For now it's just a traders share and will remain so until they get some revenue they're willing to tell us about. For holders it's one for the bottom drawer. Just my opinions and recollections may vary, dyor, etc.... |
Posted at 23/6/2023 11:27 by snowy20 Now the placing out of and the drop in price afterHow much will price move up again Update to Announcement dated 29 March 2023 - Oversubscribed £2.9 million fundraise As previously announced on 29 March 2023 (the "Fundraising Announcement"), the Company has raised £2.9 million by way of an oversubscribed placing (the "Placing") of 16,317,648 new ordinary shares in the capital of the Company ("Placing Shares") at a price of 17p per share (the "Placing Price") and additionally, the subscription of 882,352 new ordinary shares ("Subscription Shares") by investors procured directly by the Company ("Subscribers") also at the Placing Price (the "Subscription"). By way of further update, the Company has entered into deeds of variation with each of the subscribers in respect of the Subscription Shares pursuant to which 264,739 of the Subscription Shares ("Second Tranche Shares") will be allotted and issued conditional on (i) the Company convening a general meeting and obtaining approval from shareholders to disapply statutory pre-emption rights ("Resolutions") and (ii) the publication of a prospectus, as soon as reasonably practicable following Admission. The Second Tranche Shares and the Fundraising Warrants (as defined in the Fundraising Announcement) shall be allotted and issued conditional on the passing of the Resolutions and the publication of a prospectus. The Company confirms that application will be made to the Financial Conduct Authority and the London Stock Exchange for a total of 16,985,261 Ordinary shares of £0.01 each (being the aggregate of the Placing Shares, the Subscription Shares less the Second Tranche Shares and 50,000 ordinary shares issued on 9 February 2023 following the exercise of warrants) (the "Shares") to be admitted to the standard segment of the Official List and to trading on the Main Market of the London Stock Exchange ("Admission"). The Shares rank pari passu with the existing ordinary shares. Admission of the Shares is expected take place on 14 April 2023. Total Voting Rights The Fundraising Announcement had stated that the Company's issued share capital following Admission will be 86,036,937 however the correct number is 102,972,198. The full amended paragraph is set out below. Application will be made for admission of the Shares to trading on the Main Market. It is expected that Admission will be on or around 14 April 2023. The Placing Shares and the Subscription Shares will rank pari passu in all respects with the Company's existing ordinary shares. Following Admission, the total number of ordinary shares in the Company in issue will be 102,972198. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
